Videos

Riccardo Lencioni, MD, discusses how the new protocol from the phase 3 EMERALD-1 trial may be implemented in the community oncology setting for the treatment of hepatocellular carcinoma.

Marcia S. Brose, MD, PhD, FASCO, discusses her hopes for the future of selpercatinib in treating advanced or metastatic RET-mutant thyroid cancer.

Marcia S. Brose, MD, PhD, discusses treatment sequencing practices and offers advice for community oncologists treating patients with RAI-R-DTC.

Focusing on lenvatinib, an expert on RAI-R-DTC discusses data on real-world treatment patterns and clinical outcomes and gives an overview of papers on age and dose.

Marcia S. Brose, MD, PhD, discusses her experience with lenvatinib as a treatment for patients with RAI-R-DTC.

An expert on radioiodine-refractory differentiated thyroid cancer outlines factors to consider when selecting appropriate treatments for patients.

Clinical insights on the standard-of-care treatment of patients with advanced RAI-R-DTC, the NCCN guideline recommendations, and challenges encountered in treatment.

Marcia S. Brose, MD, PhD, discusses the frontline treatment landscape for patients with advanced RAI-R-DTC, focusing on sorafenib and the DECISION trial as well as lenvatinib and the SELECT trial.

A medical oncologist gives an overview of radioiodine-refractory differentiated thyroid cancer, with a focus on diagnosis and patient presentation.

Nasir Chaudry, MD, discusses treatment decisions for patients with prostate cancer and the importance of individualized treatment based on the specific case and patient preferences.

Matthew J. Frigault, MD, MS, discussed what a community oncologist should know about the ongoing FDA investigation of chimeric antigen receptor T-cell therapies.

Marcia S. Brose, MD, PhD, presents the case of a 43-year-old man with radioiodine-refractory differentiated thyroid cancer (RAI-R-DTC) and offers her initial impressions.

Experts comment on factors that influence their decision-making when treating patients with lower-risk MDS.

Insights into treatment goals and review of the current treatment landscape for lower-risk MDS.

Following their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.

Medical oncologists discuss the results from the SAVE and AUGMENT-101 clinical trials investigating revumenib in patients with acute myeloid leukemia.

Uma Borate, MBBS, and the Oncology Brothers provide insights gleaned from the MANIFEST-2 study, a phase 3, randomized, double-blind study on pelabresib plus ruxolitinib for JAK inhibitor treatment–naïve patients with myelofibrosis.

Following ASH 2023, Uma Borate, MBBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the TRANSFORM-1 trial investigating navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Dr Shadman provides an overview of zanubrutinib efficacy and safety data for relapsed/refractory CLL from the Phase 2 ALPINE trial.

An overview of highlights from ASH 2023 on integrating BTK inhibitors into frontline CLL therapy.

Dr Mazyar Shadman reviews emerging targeted therapies shaping the treatment landscape and optimal sequencing in CLL.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed data from a quality improvement initiative identifying issues for health care professionals and patients with HER2-positive breast cancer.

Two experts explore the essentials of Graft vs Host Disease (GvHD), understanding its symptoms, diagnosis, and distinguishing characteristics between acute and chronic forms.

Dr. Zeiser discusses the dynamic clinical evolution of Graft vs Host Disease (GvHD) in a concise overview, gaining insights into its progression and changing manifestations over time.

Halle Moore, MD, discusses findings from a study on young breast cancer survivors who attempted pregnancy after interrupting hormone therapy.

Expert perspectives on 2 abstracts presented at ASH 2023 looking at durable continuous transfusion independence and efficacy across different risk subgroups in the IMerge phase 3 trial in MDS.

Gary J. Schiller, MD, a hematologist/oncologist, discusses the current treatment landscape for patients with lower-risk myelodysplastic syndrome [MDS].

Julie Chang, MD, discusses the reasoning behind the development of a minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma.

Brea C. Lipe, MD highlights key takeaways and patient outcomes from the PERSEUS phase three trial.

Brea C. Lipe, MD explains the trial design and patient population of PERSEUS phase three trial.